Kane Biotech (CVE:KNE) Shares Up 20% – Should You Buy?

Kane Biotech Inc. (CVE:KNE) rose 20% during mid-day trading on Thursday . The stock traded as high as C$0.03 and last traded at C$0.03. Approximately 157,000 shares changed hands during mid-day trading, a decline of 4% from the average session volume of 163,535 shares. The stock had previously closed at C$0.03.

Kane Biotech Price Performance

The company has a debt-to-equity ratio of -135.17, a quick ratio of 0.39 and a current ratio of 0.45. The business has a 50-day simple moving average of C$0.03 and a 200 day simple moving average of C$0.03. The firm has a market cap of C$6.15 million, a P/E ratio of -3.00 and a beta of 1.05.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.